In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Succession

Executive Summary

Chairman Roy Vagelos reiterates Nov. 1, 1994 resignation date. Medco Chairman Marty Wygod is not a candidate to succeed, Vagelos tells annual meeting. Merck board -- nine outsiders and Vagelos and Wygod -- is well into succession issue, Vagelos reports. The Merck chairman -- an inveterate recruiter and talent selector -- has made inquiries outside the company about potential senior managers in the past year. A board dominated by outsiders may also be tempted to look beyond current management without a clear heir- apparent. Exec VP Edward Scolnick (research) and Senior VP-CFO Judy Lewent have been given the most visible outside roles as spokespeople for the firm in recent months
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS024410

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel